Commercialization of Biosimilars to Benefit Healthcare Supply Chain of US
The profit and revenue opportunities from the commercialization of the biosimilars can possibly be responsible in enhancing the credit profiles of the companies throughout the healthcare supply chain of the United States, but there are certain obstacles to the launch of the product after getting the approval from the US FDA. The legislation introduced for […]
Continue Reading